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A B S T R A C T
Recent research data have shown that systemic administration of pyruvate and oxaloacetate causes an
increased brain-to-blood glutamate efﬂux. Since increased release of glutamate during epileptic seizures
can lead to excitotoxicity and neuronal cell death, we tested the hypothesis that glutamate scavenging
mediated by pyruvate and oxaloacetate systemic administration could have a neuroprotective effect in
rats subjected to status epilepticus (SE). SE was induced by a single dose of pilocarpine (350 mg/kg i.p.).
Thirty minutes after SE onset, a single dose of pyruvate (250 mg/kg i.p.), oxaloacetate (1.4 mg/kg i.p.), or
both substances was administrated. Acute neuronal loss in hippocampal regions CA1 and hilus was
quantitatively determined ﬁve hours after SE onset, using the optical fractionator method for
stereological cell counting. Apoptotic cascade in the hippocampus was also investigated seven days after
SE using caspase-1 and -3 activity assays. SE-induced neuronal loss in CA1 was completely prevented in
rats treated with pyruvate plus oxaloacetate. The SE-induced caspase-1 activation was signiﬁcantly
reduced when rats were treated with oxaloacetate or pyruvate plus oxaloacetate. The treatment with
pyruvate and oxaloacetate caused a neuroprotective effect in rats subjected to pilocarpine-induced SE.
 2010 Elsevier Ltd. Open access under the Elsevier OA license.
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Glutamate (Glu) is the major excitatory neurotransmitter in
the nervous system. Glu regulates many brain functions and its
synaptic concentration must be precisely controlled to avoid
excessive excitation and toxicity. As amatter of fact, the brain has
at least two mechanisms to control Glu extracellular concentra-
tion. The ﬁrst is credited mainly to the presence, both on nerve
terminals and on astrocytes, of members of a large family of Na+-
dependent Glu transporters which bind and take up Glu. This
system ensures that the very high concentrations of Glu,
transiently present after synaptic or astrocytic release, are soon
decreased to concentrations at which Glu exerts neither overt
excitatory nor excitotoxic activities (Danbolt, 2001; Sattler and
Tymianski, 2001). The second mechanism accounts for the
elimination of Glu from brain into blood in the face of an
unfavorable concentration gradient between interstitial/cerebro-
spinal ﬂuids (ISF/CSF) Glu and blood plasma (O’Kane et al., 1999).
According to this mechanism, extracellular Glu is transported via* Corresponding author at: Av. Ana Costa, 95, CEP 11060-001, Santos/SP, Brazil.
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doi:10.1016/j.neuint.2010.12.014Na+-dependent transporters, located on the antiluminal mem-
brane of brain capillaries being concentrated and accumulates
into endothelial cells. When its concentration exceeds those
found in plasma, Glu is facilitatively transported across the
luminal membrane into blood. The brain-to-blood Glu efﬂux may
also involve a glutamate–glutamine (Gln) cycle (yet to be
demonstrated) between astroglial end feet and endothelial cells.
In this pathway, excess Glu is transported into the astrocytic end
feetwhere it is converted into Gln via theGln synthetase. Gln exits
from the end feet and is untaken by Gln transporters, present on
the juxtaposed abluminalmembrane of capillary endothelial cells
(Lee et al., 1998). Once into the endothelial cell, Gln is converted
back to Glu via the endothelial glutaminase, which now diffuses
into the blood by facilitative transport. Such a mechanism could
also sub-serve a neurometabolic coupling (Jakovcevic andHarder,
2007).
Under pathological conditions involving a brain insult such as
ischemic stroke, traumatic brain injury or prolonged epileptic
seizures, Glu is uncontrollably released from its neuronal and glial
stores, via the reverse operation of the excitatory amino acid
transporters (EAATs) (Vesce et al., 2007). In these circumstances,
excess Glu is also regulated by the transporters associatedwith the
ubiquitous and dense network of brain capillaries, leading to
excitotoxic neuronal death in very large brain territories.
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associated with excessive Glu release, is the status epilepticus
(SE). SE is deﬁned as an epileptic seizure lasting more than 30 min
or as intermittent seizures, lasting for more than 30 min, during
which the patient does not recover consciousness between
repeated episodes (Leite et al., 2006). SE is one of the most
common neurological emergencies and several prospective studies
have reported an incidence of 10–20/100,000 amongst whites in
Europe and the US (Hesdorffer et al., 1998; Coeytaux et al., 2000;
Knake et al., 2001). Convulsive SE is the commonest form,
representing 40–60% of all SE cases. Mortality is high, with one out
of ﬁve dying in the ﬁrst 30 days (Logroscino et al., 1997). The main
neurological sequels of SE reported in the literature are cognitive
impairment, brain damage-related deﬁcits, and long-term devel-
opment of recurrent seizures (Leite et al., 2006).
Neurobiological substrate of SE-related brain damage includes
the excitotoxic effect of excitatory amino acids, particularly Glu
(Ben-Ari and Schwarcz, 1986; Choi, 1988;Naffah-Mazzacoratti and
Amado, 2002). Intense seizure activity causes massive Ca2+ inﬂux,
which results in increased intracellular and intra-mitochondrial
membrane depolarization, superoxide production and activation
of caspases (Gupta and Dettbarn, 2003; Persike et al., 2008;
Henshall, 2007). The large increase in cytosolic Ca2+ evoked by
activation of Glu receptors (NMDA and AMPA/kainate) seems to be
a necessary step in the overall process of neuronal degeneration.
This process triggers the acute neuronal cell death that occurs after
SE (Maus et al., 1999; Fujikawa et al., 2000; Men et al., 2000).
Gottlieb et al. (2003) recently tested the hypothesis that a
larger Glu concentration gradient between ISF/CSF and blood
plasma could provide an increased driving force for the brain-to-
blood Glu efﬂux. To achieve a decrease of blood Glu levels, they
made use of the Glu scavenging properties of the blood resident
enzymes glutamate-pyruvate transaminase (GPT) and glutamate-
oxaloacetate transaminase (GOT), which transform Glu into 2-
ketoglutarate in the presence of the respective Glu co-substrates,
pyruvate (Pyr) and oxaloacetate (Oxa). They showed that the
intravenous administration of Pyr and Oxa, which decreases blood
Glu levels, accelerates the brain-to-blood Glu efﬂux. These results
support the conclusion that the brain-to-blood Glu efﬂux can be
modulated by changes in blood Glu levels and can be accelerated
by blood Glu scavenging (Gottlieb et al., 2003). Accordingly,
Zlotnik and colleagues recently tested the effects of blood Glu
scavengers in a rat model of closed head injury (CHI) and observed
a signiﬁcant improvement of the neurological recovery in the Oxa-
treated and Pyr-treated rats when compared with saline-treated
controls (Zlotnik et al., 2007, 2008).
On these bases, we hypothesized that blood Glu scavenging
induced by systemic Pyr and Oxa administration could be
neuroprotective by increasing brain-to-blood Glu efﬂux and thus
preventing excitotoxic neuronal cell damage caused by prolonged
epileptic seizures. In order to test this hypothesis, in the present
investigation we studied the effect of Pyr and Oxa administration
in rats subjected to pilocarpine-induced SE (Cavalheiro, 1995).
Pilocarpine-induced SE is a widely used model to study neuro-
degeneration in limbic structures after prolonged epileptic
seizures, particularly the hippocampal formation (Cavalheiro
et al., 1991).
2. Material and methods
2.1. Status epilepticus induction
Male Wistar rats (weight 250 g) were housed in groups of ﬁve under a
continuous 12 h/12 h light/dark cycle and had free access to food and water.
Experimental rats were injected with 4% pilocarpine hydrochloride (350 mg/kg i.p.,
Merck). Scopolamine methyl nitrate (1 mg/kg s.c., Sigma) was injected 30 min
before pilocarpine to reduce the peripheral cholinergic effects. Approximately
10 min after pilocarpine injection, animals developed partial limbic seizures withsecondary generalization leading to self-sustained SE (Turski et al., 1983). After ﬁve
hours, SE was blocked with diazepam (10 mg/kg i.p.). A control group received
saline instead of pilocarpine (Group Saline).
2.2. Pyruvate and oxaloacetate administration
Based on previous experiments designed to evaluate the neuroprotective effect
of pyruvate and oxaloacetate in vivo (Lee et al., 2001; Gottlieb et al., 2003;
Gonzales-Falcon et al., 2003; Zlotnik et al., 2007), pyruvate solution (250 mg/kg,
i.p., pH 7.4, Alfa Aesar) (Group Pilo + Pyr), oxaloacetate solution (1.4 mg/kg, i.p., pH
7.4, Calbiochem) (Group Pilo + Oxa) or both substances (Group Pilo + Pyr + Oxa)
were administrated as single injection (1.5 ml) to rats thirty minutes after the
development of SE. A control group received the same volume of saline instead of
pyruvate and oxaloacetate (Group Pilo + Saline). Survival rates for each experimen-
tal group were calculated.
The effect of Pyr and Oxa administration on brain damagewas studied ﬁve hours
after SE onset (neuronal cell counting) and seven days later (caspase activation).
These time points were chosen in order to estimate the impact of the treatment on
acute/necrotic and late/apoptotic cell death (Fujikawa, 1996; Weise et al., 2005).
2.3. Perfusion, histology and neuronal cell counting
Rats were anaesthetized with chloral hydrate and transcardially perfused with a
solution of paraformaldehyde (PF 4%) in phosphate buffer (PB 0.1 M). The brains
were removed immediately after perfusion and post-ﬁxed with a solution of PF 4%
and sucrose (30%) in PB 0.1 M. Fifty-micron coronal sections through the entire
extension of the hippocampuswere obtained using a cryostat (18 8C), mounted on
glass slides, and stained with cresyl violet (Nissl).
The estimative of total number of neurons in the CA1 hippocampal sub-region
and the hilus of the dentate gyrus was obtained in ﬁve animals per group using the
stereological method optical fractionator (West et al., 1991). Brieﬂy, every ﬁfth
section was selected, resulting in a section sampling fraction of 0.2 (ssf = 0.2). In
each section, the hippocampal subﬁeld CA1 and the hilus of the dentate gyrus were
identiﬁed according to a brain atlas (Paxinos and Watson, 1982). Disector counting
probes (25 mm  25mm) were uniform and randomly distributed through the
hippocampus (right and left). Each disector correspond to an area (a) of 625 mm2
and the distance between counting frames (x,y step) was 250 mm, resulting in an
area sampling fraction of 0.01 (asf = 0.01). Neuronal cell bodies (tops) were counted
through the entire thickness of each section, resulting in a thickness sampling
fraction of 1 (tsf = 1). The estimative of total neuronal cell number (N) for each
region was calculated using the formula (West et al., 1991):
N ¼
X
Q  1
ss f
 1
as f
 1
ts f
whereSQ is the number of counted neurons, tsf is the thickness sampling fraction,
asf is the area sampling fraction, and ssf is the section sampling fraction. A pilot
study showed that this sampling scheme produced acceptable coefﬁcients of error
(CE) and variance (CV) (West et al., 1991; Keuker et al., 2001).
2.4. Caspase assays
Caspase-1 and -3 activities were studied in ﬁve animals per group using the
method described by Thornberry et al. (1997) and modiﬁed by Belizario et al.
(2001). Rats were killed, hippocampi were dissected at 4 8C and added to 20 mM
HEPES buffer (pH 7.4) that contained 2 mM EDTA, 0.1% CHAPS, 10% sucrose, 0.1%
PMSF, 0.1% benzamidin, 0.1% antipain, 0.1% TLCK, 0.1% chemostatin and 0.1%
pepstatin (5ml homogenization buffer/mg tissue). Homogenates were obtained by
mechanically disrupting the tissue three times on dry-ice, with thawing in an ice
bath, interpolated by 1 min of moderate vortex shaking. Samples were centrifuged
at 12,000  g for 40 min at 4 8C to remove cellular debris. Total proteins were
determined in the supernatants using the Bio-Rad Protein Assay (Bio-Rad Labs,
Germany). Homogenates (100 mg/protein) were incubated at 37 8C with the
selective tetrapeptide substrates: Trp-Glu-His-Asp (Ac-WEHD-AMC, 4 mM) or Asp-
Glu-Val-Asp (Ac-DEVD-AMC, 4mM) for caspase-1 and -3 respectively, in a ﬁnal
volume of 150 ml. For a negative control, homogenates were pre-incubated for
10 min at 37 8C with commercial inhibitors to caspase-1 (Ac-WEHD-CHO, 1mM) or
caspase-3 (Ac-DEVD-CHO, 1 mM), followed by the addition of the respective
substrate. Activity was measured continuously over 90 min on a GENius Tecan
Austria G.M.B.H. Spectroﬂuorimeter, using lex = 360 nm and lem = 465 nm. The
peptide hydrolysis reaction velocities were expressed as units of ﬂuorescence per
min (RFU/min).
2.5. Statistics
Variance analysis (Two-way ANOVA) and Bonferroni post hoc were used to
compare the estimative of neuronal cell numbers, including the right and left
hemispheres. Data are presented as mean  S.E. and differences were considered
signiﬁcant when p  0.05. One-way ANOVA followed by Tukey’s test was used to
compare the activity of the different caspases. Data are presented as mean  S.D. and
Table 1
Neuronal cell counting and caspases activities in the hippocampus of experimental and control groups. Values for cell counts (absolute numbers) and caspases activities (RFU/
min/mg of protein) are expressed as means standard deviation.
Groups CA1 (number of cells103) Hilus (number of cells103) Caspase-1 (WEHDase activity) Caspase-3 (DEVDase activity)
Control 219.824.9 60.07.8 2318 54
Pilo+ Saline 167.531.0a 39.23.8a 5311c 112c
Pilo+Pyr 184.610.2 52.89.5 4115c 113c
Pilo+Oxa 183.312.7 39.66.2 323c,d 92c
Pilo+Pyr+Oxa 233.613.0b 47.98.6 356c,e 103c
a p<0.05 compared with control group (saline).
b p<0.05 compared with groups pilo + saline, pilo +pyr and pilo +oxa.
c p<0.001 compared with control group (saline).
d p<0.01 compared with group pilo + saline.
e p<0.05 compared with group pilo + saline.
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Fisher’s exact test (table 2X4) was used to compare the survival rates in different
experimental groups.
2.6. Ethics
All procedures were approved by the Local Ethics Committee (CEP. 1913/06) and
are in accordance with the National Institutes of Health Guide for the Care and Use
of Laboratory Animals. Every effort was taken to minimize the number of animal
used and distress of the animals.
3. Results
3.1. Neuronal cell counting
A signiﬁcant reduction of hippocampal neurons (CA1 and hilus)
was observed in the group Pilo + Saline, when compared to the
control group Saline + Saline (Table 1, Fig. 1). SE-induced neuronal
loss in CA1was completely prevented in rats treatedwith pyruvate
plus oxaloacetate (Group Pilo + Pyr + Oxa). Treatment with pyru-
vate or oxaloacetate alone did not prevent neuronal loss in CA1. On
the other hand, SE-induced neuronal loss in the hilus was
prevented only in rats that received pyruvate alone (Group
Pilo + Pyr).
3.2. Caspases activity
Seven days after pilocarpine-induced SE, a signiﬁcant increase
in the caspase-1 and caspase-3 activity was observed in all
experimental groups when compared to controls (p < 0.001)
(Table 1). Treatment with Oxa and Pyr + Oxa to rats presenting
SE, reduced signiﬁcantly the caspase-1 activation in the hippo-
campus whereas have no effect on caspase-3.
3.3. Effects on SE severity
The administration of pyruvate or oxaloacetate did not change
seizure semiology and severity during SE in experimental rats.
Mortality during SE was 34% in the group Pilo + Saline, 29% in the
group Pilo + Pyruvate, 7% in the group Pilo + Oxa and 25% in the
group Pilo + Pyr + Oxa. Fisher’s exact test did not show signiﬁcant
differences amongst groups (P = 0.38).
4. Discussion
In humans, several brain insults are characterized by excessive
Glu brain levels. These include acute disorders such as stroke,
traumatic brain injury, bacterialmeningitis and prolonged seizures
(Castillo et al., 1996; Spranger et al., 1996; Zauner et al., 1996;Men
et al., 2000; Ma et al., 2003) or chronic diseases such as glaucoma,
amyotrophic lateral sclerosis or human immunodeﬁciency virus
dementia (Shaw et al., 1995; Ferrarese et al., 2001; Spreux-
Varoquaux et al., 2002). We focused our study on epilepticseizures, particularly SE, since it is not only accompanied by a large
increase of Glu in brain ﬂuids but there is also a tight correlation
between SE-related brain damage and the development of chronic
epilepsy (Olney, 1985; Leite et al., 1990; Cavalheiro et al., 1991;
Lemos and Cavalheiro, 1995; Fujikawa, 2005).
The pilocarpine model is one of the most commonly studied
chemical-inductive models for epilepsy (Turski et al., 1983, 1986;
Leite et al., 1990; Cavalheiro et al., 1991; Cavalheiro, 1995; Arida
et al., 2006; Curia et al., 2008). Morphological analysis of the brain
after pilocarpine-induced SE demonstrates that the hippocampal
subﬁeld CA1 and the hilus of dentate gyrus are particularly
susceptible to neuronal cell loss (Turski et al., 1983, 1986).
Neuronal death occurs mainly by excitoxic injury caused by the
activation of glutamatergic pathways in the course of SE
(Cavalheiro et al., 1994; Costa et al., 2004). In the present
investigation, SE-induced neuronal loss in CA1 was completely
prevented in rats treated with Pyr plus Oxa. Moreover, neuronal
damage in the hilus was prevented in rats that received Pyr alone.
These results conﬁrm previous studies showing the neuroprotec-
tive effect of Pyr (Izumi et al., 1994; Maus et al., 1999; Monaghan
et al., 1989; Lee et al., 2001; Gonzales-Falcon et al., 2003). This
neuroprotective effect is related to the potential of Pyr and Oxa to
activate the blood resident enzymes GTP and GOT which increases
the brain-to-blood Glu efﬂux (O’Kane et al., 1999; Gottlieb et al.,
2003). Other hypothesis for the neuroprotective effect of Pyr and
Oxa is related with the capacity of these subtracts to cross
hematoencephalic barrier and normalize ATP and NAD+ (Sheline
et al., 2000; Lee et al., 2001). For instance, Oxa can contribute to an
improvement of NAD-linked mitochondrial energetics, via an
enhancement of malate-aspartate shuttle, which increases hydro-
gen peroxide scavenging (Desagher et al., 1997; Zlotnik et al.,
2007). In our experiments, we did not observe signiﬁcant
neuroprotective effects of Oxa (alone) during pilocarpine-induced
SE. In fact our results suggest a neuroprotective effect of Oxa only
when it is associated with Pyr. Further experiments must be done
in order to test the efﬁcacy of different protocols for Oxa
administration in preventing neuronal damage induced by SE.
It is noteworthy that the quantitative techniques used here
were sufﬁciently sensitive to detect even small changes in
neuron number. Coefﬁcients of error provide a standardized
statistic for evaluating the precision of neuron number
estimates derived by modern stereological techniques (Slo-
mianka and West, 2005). Averaged across animals in each
experimental group, this parameter ranged from less than 5% in
the CA1 pyramidal cell ﬁeld to less than 3% for the hilus of the
dentate gyrus. The total number of hilar neurons per hippocam-
pus computed in the present study (39.200  3.882) compares
closely to the number reported by Jiao and Nadler (2007)
(37.580  1.594), Buckmaster and Dudek (1997)
(41.093  1.284), who used essentially the same optical disector
approach, and by Miki et al., 2005 (35.200  1.600), who used a
physical disector approach. The similarity of our results with
[()TD$FIG]
Fig. 1.Representative pictures of panoramic (A, D) and high (B, E)magniﬁcation views of the hippocampal subﬁelds and respective neuronal cell counts (C, F). Panels A, B and C
represent the CA1 subﬁeld (white arrowheads). Panels D, E and F represent the hilus of the dentate gyrus (black arrowhead). Calibration bars correspond to 100 microns. (a)
p < 0.05 compared with control group (naive). (b) p < 0.05 compared with groups pilo + saline, pilo + pyr and pilo + oxa.
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stereological estimates of neuronal number.
Previous studies on pilocarpine model showed that cell death
occurs by necrosis or apoptosis (Fujikawa, 1996, 2005; Fujikawa et
al., 2000, 2002, 2007; Henshall, 2007). In contrast to acute cell
death, which occurs in the ﬁrst 24–48 h and is predominantly
necrotic, secondary or delayed neuronal cell death occurring at
later stages has been identiﬁed to be predominantly apoptotic
(Kermer and Klocker, 1999; Snider et al., 1999;Weise et al., 2005).
Caspases are considered the common apoptosis execution
pathway, and its activation raises structural alterations that
characterize apoptosis (Henkart and Gristein, 1996). In the present
investigation, we evaluated two types of caspases: caspase-1,
related with inﬂammatory process, and caspase-3, which executes
the apoptosis (Earnshaw et al., 1999; Henkart and Gristein, 1996).
As previously demonstrated in the pilocarpine model (Persike et
al., 2008) we also observed an increased activity of caspases-1 and
-3 seven days after SE. Treatment with Pyr and/or Oxa did not
prevent the increase of caspases activation, but it was signiﬁcantly
less pronounced (only for caspase-1) when rats were treated with
Oxa or Pyr + Oxa. This result suggests that early Glu scavenging did
not prevent late apoptotic neuronal cell death. In fact, Weise et al.
(2005) observed that signiﬁcant neuronal cell loss occurred in
brain regions that showed activated caspase-3 expression. Areas
with the highest levels of activated caspase-3 expression displayed
the most extensive neuronal cell loss (Weise et al., 2005). In the
present work, the increase of caspase-3 activity was not modiﬁed
by Pyr and/or Oxa administration 30 min after SE. Nevertheless, it
remains to be determined if late or prolonged Glu scavenging
prevents SE-induced caspase activation and late neuronal cell loss.
Blood glutamate scavenging has been demonstrated to be
neuroprotective in terms of neurological outcome. Zlotnik and
colleagues tested the hypothesis that Pyr- or Oxa-mediated blood
Glu scavenging causes neuroprotection in a rat model of closed
head injury (CHI), in which there is a well established deleterious
increase of Glu in brain ﬂuids. They observed highly signiﬁcant
improvements of the neurological status of rats submitted to CHI
following an intravenous treatment with Pyr or Oxa (Zlotnik et al.,
2007, 2008). The neuroprotective effects of Pyr contrast with those
observed following Oxa treatment since the neurological recovery
of rats treated with Oxa after CHI was more complete and in
markedly stronger correlation with the decrease of blood Glulevels. Thus, unlike Oxa that was suggested to exert its
neuroprotective effects mainly via its blood Glu scavenging
activity, Pyr is likely to use additional neuroprotectivemechanisms
particularly when administered at high doses (Zlotnik et al., 2008).
Although these conclusions were taken from a rat model of CHI,
some may be applied to our model of acute SE since both models
involve Glu-mediated brain injury. Future investigations focused
on long term behavioral outcome after SE may also include the
monitoring for the occurrence of spontaneous recurrent seizures
which are the hallmark the chronic phase of the pilocarpine model
of epilepsy (Arida et al., 2006; Leite et al., 2006).
As stated above, previous studies have demonstrated that
systemic administration of Pyr and Oxa in rats produces blood Glu
scavenging and increased brain-to-blood Glu efﬂux (Gottlieb et al.,
2003; Zlotnik et al., 2007, 2008). In this context, an important issue
to be addressed is the impact of Glu drop off on brain tissue,
particularly neuronal cells. Preliminary results of our group
indicate that naive animals (not subjected to SE) that received
Pyr or Pyr + Oxa show neuronal damage in the hippocampus
(unpublished data). Moreover, Gonzalez et al. (2005) showed that
rapid injection of large doses of Pyr (1–2 g/kg, i.v.) in naive rats
produced a proconvulsive effect. These ﬁndings suggest that
further experiments must be conducted in order to evaluate the
possible deleterious effects of abnormal brain-to-blood Glu efﬂux
on brain tissue.
5. Conclusion
The acute neuronal cell loss in the hippocampus (CA1 subﬁeld)
induced by SE was completely prevented in rats treated with
pyruvate plus oxaloacetate. Moreover, the late caspase-1 activa-
tion was signiﬁcantly reduced when rats were treated with
oxaloacetate or pyruvate plus oxaloacetate. These data support the
idea that the treatment with pyruvate and oxaloacetate causes a
neuroprotective effect in rats subjected to pilocarpine-induced SE.
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